Cargando…
A Novel Intravesical Dextrose Injection Improves Lower Urinary Tract Symptoms on Interstitial Cystitis/Bladder Pain Syndrome
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a painful recurrent condition characterized by the discomfort of the bladder, and current treatment options have limited effectiveness. Prolotherapy is a well-known treatment that involves the injection of non-biologic solutions to reduce pain...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715092/ https://www.ncbi.nlm.nih.gov/pubmed/34975473 http://dx.doi.org/10.3389/fphar.2021.755615 |
_version_ | 1784624065167753216 |
---|---|
author | Chen, Chin-Li Kao, Chien-Chang Yang, Ming-Hsin Fan, Gang-Yi Cherng, Juin-Hong Tsao, Chih-Wei Wu, Sheng-Tang Cha, Tai-Lung Meng, En |
author_facet | Chen, Chin-Li Kao, Chien-Chang Yang, Ming-Hsin Fan, Gang-Yi Cherng, Juin-Hong Tsao, Chih-Wei Wu, Sheng-Tang Cha, Tai-Lung Meng, En |
author_sort | Chen, Chin-Li |
collection | PubMed |
description | Interstitial cystitis/bladder pain syndrome (IC/BPS) is a painful recurrent condition characterized by the discomfort of the bladder, and current treatment options have limited effectiveness. Prolotherapy is a well-known treatment that involves the injection of non-biologic solutions to reduce pain and/or promote proliferation of soft tissue, and dextrose is the most common injectate. This study investigated the effects of dextrose prolotherapy in a rat model of IC/BPS and patients with IC/BPS. We used cyclophosphamide to induce IC/BPS in rats, and intravesical instillation of 10% dextrose solution was performed. After 1 week, we conducted a urodynamic test, bladder staining, and ECM-related gene expression analysis to examine the treatment’s efficacy. We found that dextrose treatment could recover the instability of the bladder, reduce frequent urination, and improve the glycosaminoglycan layer regeneration and the bladder wall thickness along with a significant intense expression of CD44 receptors. Furthermore, we enrolled 29 IC/BPS patients with previous hyaluronic acid/Botox treatment for more than 6 months with remained unchanged condition. In this study, they received intravesical injections of 10% dextrose solution followed by assessments for up to 12 weeks. Patient characteristics and a 3-day voiding diary before treatment were recorded. Patient responses were examined using IC/BPS-related questionnaires. Moreover, expressions of growth factors and cytokines were analyzed. The results demonstrated that dextrose prolotherapy in patients with IC/BPS reduced the frequency of treatment over time, with the mean number of treatments being 3.03 ± 1.52, and significantly reduced the incidence of nocturia and questionnaire scores associated with symptoms. Dextrose prolotherapy significantly enhanced EGF level and, in contrast, reduced the level of HGF, PIGF-1, and VEGF-D after several weeks following treatment. The cytokine analysis showed that the expressions of IL-12p70 and IL-10 were significantly up-regulated after dextrose prolotherapy in IC/BPS patients. The levels of most growth factors and cytokines in IC/BPS patients had no significant difference and showed a similar tendency as time progressed when compared to healthy controls. Overall, the alteration of growth factors and cytokines exhibited safe treatment and potential stimulation of tissue remodeling. In summary, our study demonstrated that dextrose prolotherapy is a promising treatment strategy for IC/BPS disease management. |
format | Online Article Text |
id | pubmed-8715092 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87150922021-12-30 A Novel Intravesical Dextrose Injection Improves Lower Urinary Tract Symptoms on Interstitial Cystitis/Bladder Pain Syndrome Chen, Chin-Li Kao, Chien-Chang Yang, Ming-Hsin Fan, Gang-Yi Cherng, Juin-Hong Tsao, Chih-Wei Wu, Sheng-Tang Cha, Tai-Lung Meng, En Front Pharmacol Pharmacology Interstitial cystitis/bladder pain syndrome (IC/BPS) is a painful recurrent condition characterized by the discomfort of the bladder, and current treatment options have limited effectiveness. Prolotherapy is a well-known treatment that involves the injection of non-biologic solutions to reduce pain and/or promote proliferation of soft tissue, and dextrose is the most common injectate. This study investigated the effects of dextrose prolotherapy in a rat model of IC/BPS and patients with IC/BPS. We used cyclophosphamide to induce IC/BPS in rats, and intravesical instillation of 10% dextrose solution was performed. After 1 week, we conducted a urodynamic test, bladder staining, and ECM-related gene expression analysis to examine the treatment’s efficacy. We found that dextrose treatment could recover the instability of the bladder, reduce frequent urination, and improve the glycosaminoglycan layer regeneration and the bladder wall thickness along with a significant intense expression of CD44 receptors. Furthermore, we enrolled 29 IC/BPS patients with previous hyaluronic acid/Botox treatment for more than 6 months with remained unchanged condition. In this study, they received intravesical injections of 10% dextrose solution followed by assessments for up to 12 weeks. Patient characteristics and a 3-day voiding diary before treatment were recorded. Patient responses were examined using IC/BPS-related questionnaires. Moreover, expressions of growth factors and cytokines were analyzed. The results demonstrated that dextrose prolotherapy in patients with IC/BPS reduced the frequency of treatment over time, with the mean number of treatments being 3.03 ± 1.52, and significantly reduced the incidence of nocturia and questionnaire scores associated with symptoms. Dextrose prolotherapy significantly enhanced EGF level and, in contrast, reduced the level of HGF, PIGF-1, and VEGF-D after several weeks following treatment. The cytokine analysis showed that the expressions of IL-12p70 and IL-10 were significantly up-regulated after dextrose prolotherapy in IC/BPS patients. The levels of most growth factors and cytokines in IC/BPS patients had no significant difference and showed a similar tendency as time progressed when compared to healthy controls. Overall, the alteration of growth factors and cytokines exhibited safe treatment and potential stimulation of tissue remodeling. In summary, our study demonstrated that dextrose prolotherapy is a promising treatment strategy for IC/BPS disease management. Frontiers Media S.A. 2021-12-15 /pmc/articles/PMC8715092/ /pubmed/34975473 http://dx.doi.org/10.3389/fphar.2021.755615 Text en Copyright © 2021 Chen, Kao, Yang, Fan, Cherng, Tsao, Wu, Cha and Meng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Chen, Chin-Li Kao, Chien-Chang Yang, Ming-Hsin Fan, Gang-Yi Cherng, Juin-Hong Tsao, Chih-Wei Wu, Sheng-Tang Cha, Tai-Lung Meng, En A Novel Intravesical Dextrose Injection Improves Lower Urinary Tract Symptoms on Interstitial Cystitis/Bladder Pain Syndrome |
title | A Novel Intravesical Dextrose Injection Improves Lower Urinary Tract Symptoms on Interstitial Cystitis/Bladder Pain Syndrome |
title_full | A Novel Intravesical Dextrose Injection Improves Lower Urinary Tract Symptoms on Interstitial Cystitis/Bladder Pain Syndrome |
title_fullStr | A Novel Intravesical Dextrose Injection Improves Lower Urinary Tract Symptoms on Interstitial Cystitis/Bladder Pain Syndrome |
title_full_unstemmed | A Novel Intravesical Dextrose Injection Improves Lower Urinary Tract Symptoms on Interstitial Cystitis/Bladder Pain Syndrome |
title_short | A Novel Intravesical Dextrose Injection Improves Lower Urinary Tract Symptoms on Interstitial Cystitis/Bladder Pain Syndrome |
title_sort | novel intravesical dextrose injection improves lower urinary tract symptoms on interstitial cystitis/bladder pain syndrome |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715092/ https://www.ncbi.nlm.nih.gov/pubmed/34975473 http://dx.doi.org/10.3389/fphar.2021.755615 |
work_keys_str_mv | AT chenchinli anovelintravesicaldextroseinjectionimproveslowerurinarytractsymptomsoninterstitialcystitisbladderpainsyndrome AT kaochienchang anovelintravesicaldextroseinjectionimproveslowerurinarytractsymptomsoninterstitialcystitisbladderpainsyndrome AT yangminghsin anovelintravesicaldextroseinjectionimproveslowerurinarytractsymptomsoninterstitialcystitisbladderpainsyndrome AT fangangyi anovelintravesicaldextroseinjectionimproveslowerurinarytractsymptomsoninterstitialcystitisbladderpainsyndrome AT cherngjuinhong anovelintravesicaldextroseinjectionimproveslowerurinarytractsymptomsoninterstitialcystitisbladderpainsyndrome AT tsaochihwei anovelintravesicaldextroseinjectionimproveslowerurinarytractsymptomsoninterstitialcystitisbladderpainsyndrome AT wushengtang anovelintravesicaldextroseinjectionimproveslowerurinarytractsymptomsoninterstitialcystitisbladderpainsyndrome AT chatailung anovelintravesicaldextroseinjectionimproveslowerurinarytractsymptomsoninterstitialcystitisbladderpainsyndrome AT mengen anovelintravesicaldextroseinjectionimproveslowerurinarytractsymptomsoninterstitialcystitisbladderpainsyndrome AT chenchinli novelintravesicaldextroseinjectionimproveslowerurinarytractsymptomsoninterstitialcystitisbladderpainsyndrome AT kaochienchang novelintravesicaldextroseinjectionimproveslowerurinarytractsymptomsoninterstitialcystitisbladderpainsyndrome AT yangminghsin novelintravesicaldextroseinjectionimproveslowerurinarytractsymptomsoninterstitialcystitisbladderpainsyndrome AT fangangyi novelintravesicaldextroseinjectionimproveslowerurinarytractsymptomsoninterstitialcystitisbladderpainsyndrome AT cherngjuinhong novelintravesicaldextroseinjectionimproveslowerurinarytractsymptomsoninterstitialcystitisbladderpainsyndrome AT tsaochihwei novelintravesicaldextroseinjectionimproveslowerurinarytractsymptomsoninterstitialcystitisbladderpainsyndrome AT wushengtang novelintravesicaldextroseinjectionimproveslowerurinarytractsymptomsoninterstitialcystitisbladderpainsyndrome AT chatailung novelintravesicaldextroseinjectionimproveslowerurinarytractsymptomsoninterstitialcystitisbladderpainsyndrome AT mengen novelintravesicaldextroseinjectionimproveslowerurinarytractsymptomsoninterstitialcystitisbladderpainsyndrome |